Based on PVR expression levels, the somatic mutation profiles revealed that mutations in TP53 (47%), TTN (45%), KMT2D (29%), MUC16 (27%), KDM6A (26%), ARID1A (24%), PIK3CA (21%) were significantly enriched in BLCA samples (Supplementary Figure 1A). This evidence concerns the gene PVR and bladder transitional cell carcinoma.